ArticleAnnals of nuclear medicine2025
Multimodal imaging analysis of autosomal recessive Parkinson's disease.
Article in Annals of nuclear medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Tracking Genetic Parkinson's Disease with Molecular Imaging: A Systematic Review.Movement disorders clinical practice · 2026Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivePathophysiological backgrounds of idiopathic Parkinson's disease (IPD) and autosomal recessive monogenic Parkinson's disease (AR-PD) have common features that can be assessed through multimodal imaging. In this study, the striatal and myocardial dopaminergic innervation, brain 18F-FDG metabolism, resting-state functional activity of basal ganglia network (BGN) and white-matter (WM) microstructure were evaluated in AR-PD with respect to IPD, to investigate whether AR-PD can be subtyped as "brain-first" parkinsonism according to recent etiopathogenetic classification effort.
methodsForty patients (17 with Parkin, 3 with DJ-1 mutations and 20 with IPD) were included. Striatal dopaminergic innervation was assessed semi-quantitatively by 18F-DOPA PET, and cardiac 18F-DOPA uptake was also evaluated. Brain 18F-FDG PET images were evaluated visually. Resting-state functional MRI and diffusion tensor imaging (DTI) were used to assess the BGN activity and WM microstructural alterations.
resultsAR-PD patients showed significantly decreased 18F-DOPA uptake in caudate corpus compared to both IPD and controls, with a more symmetrical striatal dopaminergic denervation. Myocardial 18F-DOPA uptake in AR-PD was similar to controls, while it was significantly reduced in IPD. There was no significant difference in cortical 18F-FDG metabolism and functional activity of BGN between PD groups. The DTI data revealed more extensive WM microstructural damage in AR-PD compared to IPD.
conclusionsAR-PD group showed additional significant decreased 18F-DOPA uptake in caudate corpus and more symmetrical striatal denervation. Additionally, relatively preserved myocardial innervation, cortical metabolic and WM microstructural changes suggest the possibility of "brain-first" type progression in AR-PD. Also, 18F-DOPA PET/CT may be a practical tool for evaluating dopaminergic innervation of striatum and heart together, but further evaluation is needed in this area.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.